Related Experiment Video
Updated: Jul 19, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
In silico prediction of clinical efficacy
Seth Michelson1, Anil Sehgal, Christina Friedrich
1Entelos, Inc., 110 Marsh Drive, Foster City, CA 94404, USA.
Current Opinion in Biotechnology
|October 19, 2006
Summary
Predicting drug efficacy using in silico methods can save pharmaceutical companies time and resources. These computational strategies aim to develop more targeted therapies and reduce clinical trial failures.
Area of Science:
- Pharmacology
- Computational Biology
- Drug Development
Background:
- Drug development is a high-risk, costly process with significant failure rates in clinical trials.
- There is a need for early prediction of clinical efficacy to optimize resource allocation and therapeutic outcomes.
Purpose of the Study:
- To review and highlight in silico strategies for predicting clinical efficacy.
- To emphasize the potential of computational approaches in improving drug development efficiency and personalization.
Main Methods:
- Review of prominent in silico strategies including physiological modeling, population pharmacodynamics analysis, genomic expression data analysis, Monte Carlo simulations, and predictive biosimulation.
- Discussion of how these methods provide early insights into human response to novel therapies.
Main Results:
- In silico strategies offer a means to predict clinical efficacy earlier in the drug development pipeline.
- These computational tools enhance the understanding of human response to novel therapeutics.
Conclusions:
- In silico approaches are crucial for reducing the high failure rates of drugs in clinical trials.
- The adoption of these predictive strategies can lead to more targeted and personalized medicine, saving time and resources in pharmaceutical research.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).